Table 1.
Methodological Features of the Ongoing RCTs Categorized According to Drug Class
| Total No. of Patients | Total No. of RCTs | Sample Size |
Enrolling Sites |
Comparator Types |
Blinding |
Primary Clinical Outcome | Primary Surrogate Outcome | Blinded Outcome Adjudication | Design Paper Published | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <150 Participants | >150 Participants | Single-Center | Multicenter | Placebo | SOC/No Intervention | Open Label | Single | Double | |||||||
| Statins | 18,215 | 17 | 7 | 10 | 10 | 7 | 5 | 12 | 11 | 1 | 5 | 14 | 3 | 2 | 4 |
| Fibrates | 1,050 | 3 | 1 | 2 | 1 | 2 | 3 | – | – | – | 3 | 3 | 0 | 1 | – |
| Niacin | 1,200 | 5 | 4 | 1 | 4 | 1 | 5 | – | – | – | 5 | 4 | 1 | – | – |
| Omega-3 fatty acids | 21,898 | 14 | 8 | 6 | 9 | 5 | 7 | 7 | 2 | 5 | 7 | 8 | 6 | – | 3 |
| Dalcetrapib | 227 | 1 | – | 1 | – | 1 | 1 | – | – | – | 1 | 1 | – | – | – |
SOC = standard of care; RCTs = randomized controlled trials.